Bioactive compounds: a goldmine for defining new strategies against pathogenic bacterial biofilms?


Pompilio A., Scocchi M., Mangoni M. L. , Shirooie S., Serio A., da Costa Y. F. G. , ...More

CRITICAL REVIEWS IN MICROBIOLOGY, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Publication Date: 2022
  • Doi Number: 10.1080/1040841x.2022.2038082
  • Journal Name: CRITICAL REVIEWS IN MICROBIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, Environment Index, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Keywords: Bioactive natural compounds, secondary metabolites, bacterial biofilms, antibiotic-resistance, biofilm-associated infections, QUORUM-SENSING INHIBITOR, STAPHYLOCOCCUS-AUREUS, SECONDARY METABOLITES, ANTIBIOFILM ACTIVITY, ANTIMICROBIAL PEPTIDES, IN-VITRO, ANTIBACTERIAL ACTIVITY, BIOLOGICAL-ACTIVITY, NATURAL-PRODUCTS, USNIC ACID
  • Gazi University Affiliated: Yes

Abstract

Most human infectious diseases are caused by microorganisms growing as biofilms. These three-dimensional self-organized communities are embedded in a dense matrix allowing microorganisms to persistently inhabit abiotic and biotic surfaces due to increased resistance to both antibiotics and effectors of the immune system. Consequently, there is an urgent need for novel strategies to control biofilm-associated infections. Natural products offer a vast array of chemical structures and possess a wide variety of biological properties; therefore, they have been and continue to be exploited in the search for potential biofilm inhibitors with a specific or multi-locus mechanism of action. This review provides an updated discussion of the major bioactive compounds isolated from several natural sources - such as plants, lichens, algae, microorganisms, animals, and humans - with the potential to inhibit biofilm formation and/or to disperse established biofilms by bacterial pathogens. Despite the very large number of bioactive products, their exact mechanism of action often remains to be clarified and, in some cases, the identity of the active molecule is still unknown. This knowledge gap should be filled thus allowing development of these products not only as novel drugs to combat bacterial biofilms, but also as antibiotic adjuvants to restore the therapeutic efficacy of current antibiotics.